Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus SERPASIL APRESOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus SERPASIL APRESOLINE.
DEMI-REGROTON vs SERPASIL-APRESOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases cGMP via NO).
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination